• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Peptide firm Diatide scores financing

Article

Peptide-based radiopharmaceutical Diatide of Londonderry, NH, raised $11.8 million last month through a placement of preferred stock to existing investors. The preferred stock is convertible into 1.2 million shares of Diatide common stock. Diatide

Peptide-based radiopharmaceutical Diatide of Londonderry, NH, raised $11.8 million last month through a placement of preferred stock to existing investors. The preferred stock is convertible into 1.2 million shares of Diatide common stock. Diatide executives said the funds would be used for intermediate-term financing needs, to move its late-stage products toward commercialization, and to increase R&D in the area of therapeutic agents.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.